Jérôme Braudeau

Jérôme is specialized in preclinical pharmacology, especially on neurodegenerative pathologies. He is also a co-Founder & CEO of AgenT. Combining machine learning and neuroscience, AgenT is developing the first blood diagnosis to detect Alzheimer’s disease from the silent phase. Their algorithm aims to detect the disease 10 to 20 years ahead of the current diagnosis and stratify it into silent and clinical AD phases.
Country: United States
Visit Website